SynthesisDrug design, development and therapy2026
Stachydrine: A Systematic Review of Its Multi-Targeted Therapeutic Potential in Cardiovascular, Oncology, Renal, Gynecological, and Inflammatory Disorders.
Synthesis in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Role of Pyrrolidine in Antibacterial Drug Discovery: Clinically Approved Antibiotics, Novel Derivatives, and Future Perspectives.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stachydrine, a principal bioactive alkaloid derived from Uteroprotective benefits: Stachydrine regulates uterine hemorrhage by balancing Th1/Th2/Th17/Treg immune homeostasis and modulating endothelial function (e.g. NO and endothelin-1 levels), while enhancing uterine smooth muscle contractility. Antioxidant mechanisms: It reduces oxidative stress via ROS scavenging and NOX2 pathway inhibition, thereby protecting cardiovascular and neuronal tissues. Anti-inflammatory properties: Through modulation of NF-κB, JAK2/STAT3, and AMPK/SIRT1 pathways, stachydrine alleviates acute and chronic inflammation in models ranging from arthritis to neuroinflammation. Conclusion: This review comprehensively documents stachydrine's multi-targeted and multi-organ therapeutic potential, driven by its pleiotropic mechanisms. It provides a robust foundation for clinical translation in cardiovascular diseases, cancer, renal disorders, gynecological conditions, and inflammation-associated pathologies. Future research should prioritize high-quality clinical trials and synergistic drug-combination strategies to harness its therapeutic efficacy fully.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.